What Omega Funds does

Omega Funds is a global life-sciences venture capital firm founded in 2003 (per the founder's biography) or 2004 (per the firm's Purpose page) by Otello Stampacchia and headquartered at 888 Boylston Street in Boston, Massachusetts, with a regional European office at Place du Molard 7, Geneva, Switzerland. The legal entity is Omega Fund Management, LLC, a Massachusetts-domiciled LLC. The firm operates a series of flagship investment funds — currently spanning Funds IV through VIII — and pursues a stage-agnostic investment model covering four explicit strategies: Company Creation, Primary Venture, Direct Secondaries, and Public Investments (PIPEs/IPOs). Geographic focus is concentrated in North America and Western Europe, with opportunistic global participation.

Across these strategies, Omega Funds invests in transformative life-sciences companies across therapeutic areas including oncology, immunology, rare diseases, and precision medicine, targeting exceptional founders, scientists and entrepreneurs. Since inception the firm has invested in more than 150 portfolio companies and supported 54 marketed products brought to patients, including Blincyto, Breyanzi, Kimmtrak, Imlygic, Heplisav-B, Lyxumia, Mavyret, Viekira Pak, Trilogy, Rezzayo, Rivfloza, Zoryve, Ibtrozi, Encelto, and Baxfendy. Major recent lead transactions include the $197M Alveus Therapeutics Series A, the $217M Third Arc Bio Series A, the $67M Spiro Medical Series A, the $112.5M Caldera Therapeutics launch financing, and the original $275M Nuvation Bio Series A. Realizations include the Bicara Therapeutics, Upstream Bio, Lexeo Therapeutics, Beta Bionics, Arcutis, Morphic, Prevail, Translate Bio and Trevi IPOs, and the CinCor (AstraZeneca), EyeBio (Merck), Imago BioSciences (Merck), SoniVie (Boston Scientific), Amunix (Sanofi), and Chord Therapeutics (Merck) acquisitions.

The firm employs approximately 22 named team members across five functional categories — Management, Investment Professionals, Advisors, Operations, and Administration — supplemented by portfolio board and observer seats across 20+ active investments. Revenue is generated via industry-standard fund management fees (typically 1.5–2.0% of committed capital annually) on the firm's active funds and carried interest (typically 20% above a hurdle) on successful realizations. Omega Funds maintains dedicated limited-partner portals (Altar Return for Funds VI/VII/VIII and Intralinks InvestorVision for Funds IV/V) and publishes thought-leadership content including the Omega Insights Series and Omega Position Papers.

Name

Omega Funds

Legal name

Omega Fund Management, LLC

Website

https://omegafunds.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Omega Funds is a global life-sciences venture capital firm founded in 2004 that invests stage-agnostically — from company creation through IPO — across oncology, immunology, rare diseases, and precision medicine, serving entrepreneurs and limited partners from offices in Boston and Geneva.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Capital

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

Keywords

• Life sciences venture capital
• Healthcare private equity
• Biotech investment funds
• Venture capital management
• Pharmaceutical investment firm

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Fund Management Fees (Fund VIII): In July 2025 Omega Funds closed an oversubscribed $647 million Fund VIII to invest in transformative life sciences companies. VC fund managers earn recurring management fees (industry-standard ~1.5–2% of committed capital annually during the investment period, declining during harvest) on committed and invested capital from limited partners.
2. Carried Interest (Performance Fees): As a venture capital firm, Omega Funds is entitled to a carried interest (typically 20% of net fund profits above a hurdle) on successful realizations from portfolio companies. Exits and IPOs of portfolio companies (e.g., Bicara Therapeutics $362M IPO, Upstream Bio IPO, Lexeo Therapeutics IPO, Beta Bionics IPO, CinCor Pharma acquisition by AstraZeneca, Merck acquisitions of EyeBio and Imago BioSciences, SoniVie acquisition by Boston Scientific, Amunix acquisition by Sanofi, Checkmate acquisition by Regeneron, Chord Therapeutics acquisition by Merck, etc.) generate realized returns that drive carried-interest revenue.

Go-to-market motion4 records

Marketing channels9 records

Core offering

Omega Funds is a private venture capital firm that raises and manages life-sciences-focused investment funds (most recently Omega Fund VIII at $647 million, closed 2025) and deploys the capital across four strategies: company creation, primary venture, direct secondaries, and public investments (PIPEs/IPOs) in therapeutic areas such as oncology, immunology, rare diseases and precision medicine. The firm invests in early-, mid- and late-stage life-sciences companies primarily in North America and Western Europe, providing capital plus company-building expertise and a global co-investor network.

Product overview

Omega Funds is a global life-sciences venture capital firm (founded 2004) whose offerings are a series of related flagship investment vehicles plus limited-partner services, rather than a software product. The unified offering is anchored by its family of funds — Omega Fund VIII (oversubscribed, $647M, 2025), Omega Fund VII ($650M, 2021), Omega Fund VI ($438M, 2019), and earlier vintages (Funds IV and V) — which sit on top of two operational LP portals: one hosted on AltaReturn for Funds VI, VII and VIII (omegafunds.altareturn.com) and one hosted on Intralinks for Funds IV and V (apps.intralinks.com/investorvision). Across these funds, Omega pursues four explicit investment strategies — Company Creation, Primary Venture, Direct Secondaries, and Public Investments — spanning early venture through public-market support for transformative life-sciences companies. The Omega Position Paper "AI in Drug Development and Discovery" (Oct 2025) and the Omega Insights Series webinars (covering GLP-1, AI in drug discovery, and US drug-pricing policy) sit alongside the funds as content/thought-leadership products that complement the core investing offering.

Differentiator

Problem solved

Functional benefit

Products and services

• Omega Fund VIII Oversubscribed $647 million flagship life-sciences investment fund closed in 2025 to invest in transformative life-sciences companies across stages and therapeutic areas; available to institutional limited partners.
• Omega Fund VII Seventh flagship life-sciences investment fund, an oversubscribed $650 million vehicle closed in December 2021 with emphasis on company creation; available to institutional limited partners.
• Omega Fund VI Sixth flagship life-sciences investment fund, a $438 million vehicle raised in December 2019 to invest across the future of medicine, supporting company creation, primary venture, direct secondaries, and public investments.
• Investor Portal - Omega Funds VI, VII & VIII Web portal hosted on the AltaReturn platform providing limited partners of Omega Funds VI, VII, and VIII with fund information and reporting; governed by separate terms from the public site.
• Investor Portal - Omega Funds IV & V Web portal hosted on the Intralinks platform providing limited partners of Omega Funds IV and V with fund information and reporting; governed by separate terms from the public site.
• Omega Fund V Fifth flagship life-sciences investment fund of Omega Funds; accessible to limited partners via the Intralinks investor portal.
• Omega Fund IV Fourth flagship life-sciences investment fund of Omega Funds; accessible to limited partners via the Intralinks investor portal.

Quantifiable outcome

• 54 marketed products brought to patients since inception
• +7 more outcomes

Segments5 records

Ideal customer profiles4 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core / flagship alliance - shapes omega funds' positioning on european life-sciences capital policy and is one of the firm's highest-profile coalition relationships, core / coalition founding partner and core / coalition co-founding partner and frequent co-investor.

• European Life Sciences Coalition (ELSC)core / flagship alliance - shapes omega funds' positioning on european life-sciences capital policy and is one of the firm's highest-profile coalition relationshipsOthersOmega Funds is a co-founding member of the European Life Sciences Coalition (ELSC), launched in February 2026 in collaboration with Invest Europe. Other founding members include Sofinnova Partners, Novo Holdings, Forbion, HealthCap, Cooley and Covington & Burling. The coalition collectively manages over €24 billion in life-sciences assets and aims to mobilize private and public capital to reverse Europe's share decline in global life-sciences VC (7% vs US 63% and China 14%) and stop the trend of European biotechs listing abroad (66 of 67 EU biotech IPOs in the past six years occurred outside the EU). ELSC does not seek subsidies but advocates for structural reform.
• Invest Europecore / coalition founding partnerOthersInvest Europe collaborated with the European Life Sciences Coalition (ELSC) at its launch in February 2026 alongside Omega Funds, Sofinnova Partners, Novo Holdings, Forbion, HealthCap, Cooley and Covington & Burling. ELSC aims to mobilize private and public funding to strengthen Europe's life-sciences investment environment.
• Sofinnova Partnerscore / coalition co-founding partner and frequent co-investorOthersCo-founding member of the European Life Sciences Coalition alongside Omega Funds. Sofinnova also co-led ARTBIO's $132M Series B with B Capital (August 2025), in which Omega Funds participated.
• Novo Holdingscore / coalition co-founding partner and frequent co-investorOthersCo-founding member of the European Life Sciences Coalition alongside Omega Funds. Novo Holdings also participated in the second closing of Alveus Therapeutics' oversubscribed Series A (alongside Jeito Capital), bringing the total Series A round to $197 million in February 2026.

Scale indicators12 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• OrbiMed: One of the world's largest healthcare-dedicated investment firms with multi-stage venture, royalty/credit, and public-equity strategies. Closest like-for-like to Omega across stage-agnostic life-sciences investing and is a frequent Omega co-investor (e.g., Alveus Series A syndicate).
• RA Capital Management: Healthcare-focused crossover and venture investor with strong primary, secondary, and public-market capabilities. Directly comparable stage-agnostic life-sciences model and frequent Omega co-investor (e.g., Windward Bio).
• Forbion: European life-sciences specialist with primary venture and growth strategies. Direct co-investor in Omega-led rounds (e.g., Protego Biopharma Series B with Novartis Venture Fund) and co-founding ELSC member alongside Omega.
• Sofinnova Partners: Paris- and Milan-based European life-sciences specialist across company creation and venture. Co-founding ELSC partner with Omega and a frequent co-investor (e.g., co-led ARTBIO's $132M Series B with B Capital).
• Andera Partners: Paris-based life-sciences and growth private equity firm. Co-led Omega's Alveus Therapeutics ($159.8M) and Spiro Medical ($67M) Series A rounds in January 2026, making it one of Omega's most frequent co-lead counterparties.
• Frazier Life Sciences: US healthcare-dedicated investment firm operating venture and public-equity strategies; closed a $1.3B life-sciences fund in 2025. Directly comparable stage-agnostic life-sciences model and frequent Omega co-investor.
• Atlas Venture: Early-stage life-sciences venture firm focused on company creation in Cambridge, MA. Co-invested with Omega in Caldera Therapeutics ($75M Series A) and is part of the same Boston biotech VC ecosystem.
• Novo Holdings: Denmark-based holding company of the Novo Nordisk Foundation with large-scale healthcare venture and growth strategies. Co-founding ELSC partner and a frequent Omega co-investor (e.g., second close of Alveus' $197M Series A).
• HealthCap: Nordic-European life-sciences specialist investing across venture and growth stages. Co-founding ELSC partner alongside Omega and operates a comparable stage-agnostic, therapeutics-focused European model.

Broad incumbents

• Andreessen Horowitz (a16z) Bio + Health: Generalist VC with a large, dedicated Bio + Health practice that co-leads and participates in life-sciences venture rounds (e.g., Third Arc Bio Series A extension led by a16z with Omega participation). Comparable as a healthcare venture investor but with a much broader overall fund footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/omegafunds

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments165 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Omega Funds